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What is known about the subject?
 ► Therapeutic hypothermia has a neuroprotec-
tive effect for neonates with hypoxic ischaemic 
hypothermia.
 ► Hypoxic ischaemic asphyxia and lowering the core 
body temperature has impact on the pharmacoki-
netics, up to the level that dosing regimens for these 
neonates should be adapted.
What this study adds?
 ► Compared with the latest structured review (2015) 
on pharmacokinetics during hypothermia for four 
compounds (gentamicin, topiramate, phenobarbital, 
morphine), the current systematic search provides 
data on 15 compounds, reflecting the relevant prog-
ress made.
 ► A significant decrease in clearance is observed in 
neonates during therapeutic hypothermia, be it that 
the extent differs between routes of elimination and 
compounds, but most pronounced for renal elim-
ination (phenobarbital no difference, midazolam 
metabolite −21%, lidocaine −24%; morphine −21% 
to −47%, gentamicin −25% to −35%, amikacin 
−40%) during hypothermia.
AbstrACt
background Neonatal hypoxic ischaemic 
encephalopathy due to perinatal asphyxia, can result 
in severe neurodevelopmental disability or mortality. 
Hypothermia is at present the only proven neuroprotective 
intervention. During hypothermia, the neonate may need 
a variety of drugs with their specific pharmacokinetic 
profile. The aim of this paper is to determine the effect 
that hypothermia for neonates suffering from hypoxic 
ischaemic encephalopathy has on the pharmacokinetics 
and to what extent dosing regimens need adjustments.
Method A systematic search was performed on PubMed, 
Embase and Cochrane Library of literature (2000–2020) 
using a combination of the following search terms: 
therapeutic hypothermia, neonate, hypoxic ischemic 
encephalopathy and pharmacokinetics. Titles and 
abstracts were screened, and inclusion/exclusion criteria 
were applied. Finally, relevant full texts were read, and 
secondary inclusion was applied on the identified articles.
results A total of 380 articles were retrieved, and 34 
articles included after application of inclusion/exclusion 
criteria and duplicate removal, two additional papers were 
included as suggested by the reviewers. Twelve out of 
36 studies on 15 compounds demonstrated a significant 
decrease in clearance, be it that the extent differs between 
routes of elimination and compounds, most pronounced for 
renal elimination (phenobarbital no difference, midazolam 
metabolite −21%, lidocaine −24%; morphine −21% to 
−47%, gentamicin −25% to −35%, amikacin −40%) 
during hypothermia. The data as retrieved in literature 
were subsequent compared with the dosing regimen as 
stated in the Dutch paediatric formulary.
Conclusion Depending on the drug- specific disposition 
characteristics, therapeutic hypothermia in neonates 
with hypoxic ischaemic encephalopathy affects 
pharmacokinetics.
IntroduCtIon
Neonatal hypoxic ischaemic encephalopathy 
(HIE), brain damage sustained as a result of 
perinatal asphyxia, occurs in 1.5 out of 1000 
births1 and can result in severe neurodevelop-
mental disability or mortality in respectively 
24.9% and 34.1% of cases.2 Perinatal asphyxia 
is a condition characterised by a persistently 
low Apgar score (≤5) assessed at 5 and 10 min 
after birth, or metabolic acidosis, defined as a 
pH of <7.0 and/or base deficit of ≥16 mmol/L, 
measured in the fetal umbilical artery or arte-
rial blood within 1 hour after birth.3 4 The 
HIE severity can be categorised by the Sarnat 
score into mild, moderate and severe brain 
injury based on the abnormality of level of 
consciousness, spontaneous activity, posture, 
tone, primitive reflexes and autonomic func-
tion.5 Alternatively, the Thompson score 
is another scoring system that uses similar 
criteria like Sarnat but also includes the pres-
ence of seizures and fontanelle tension; both 
scores can be used for prognosis and provide 
prognostic value and quantify HIE into mild, 
moderate and severe.6
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Figure 1 Flow chart on search strategy, search terms and 
number of hits in PubMed, Embase and Cochrane.
Therapeutic hypothermia (TH) is at present the only 
proven effective intervention for moderate and severe 
HIE. It significantly reduces the mortality by 8.8% and 
severe morbidity by 15.4% (relative risk=0.75; number 
needed to treat=7).2 In its current approach, TH aims to 
cool the body temperature of the neonate to 33.5°C for 
the duration of 72 hours within 6 hours after birth, and a 
subsequently gradual rewarming at a rate of 0.3°C–0.5°C 
per hour.7–10 According to the current guidelines all 
(near)- term neonates who meet the criteria for perinatal 
asphyxia and are classified as moderate or severe HIE by 
the Thompson score should receive this treatment.5 6
During the hypothermic period the neonate may 
need a variety of different drugs ranging from antiepi-
leptic drugs to sedatives or antibiotics. Simultaneously, 
different substances with different mechanisms involved 
are investigated on their additive neuroprotective effect. 
We refer the interested reader to a recent review on the 
pharmacodynamics of these claimed neuroprotective 
compounds.11
However, for any drug administered to these patients, 
the pharmacokinetic (PK) profile may be altered by the 
physical state of the neonate with HIE and TH. This is 
due to the altered pathophysiology explained by both 
the disease (asphyxia) and the intervention (TH), and 
includes renal impairment, altered haemodynamics like 
cardiac output and blood flow, or altered hepatic func-
tion.12 The aim of this paper is to provide an overview 
on the effects of TH in neonates suffering from HIE 
have on the PK of drugs administered during this hypo-
thermic period, and whether dosing regimens need to be 
adjusted.
Methods
A systematic search was performed on PubMed, Embase 
and Cochrane Library of all literature between 1 January 
2000 and 1 January 2020. A combination of the following 
search terms was hereby used: ‘therapeutic hypothermia, 
neonate, hypoxic ischemic encephalopathy and pharma-
cokinetics’. In PubMed the corresponding MeSH terms 
for these search terms were used. An overview of the 
performed search and the subsequent results is provided 
in figure 1.
Only articles with full- text availability written in 
English were included. Another inclusion criterion was 
the reporting of a PK parameter for at least one of the 
following processes: absorption, distribution, metabolism 
or excretion. Only studies that concerned the human 
species were included. Reviews and study protocols 
that provided no new information were excluded after 
screening references for secondary inclusion. Articles 
were excluded if the study population did not include 
term neonates or if TH was not applied.
First the titles of all articles were screened. If the rele-
vance was unsure, the abstract was subsequently read. 
Finally, the resulting selected articles were thoroughly 
studied, and the references screened for secondary 
inclusion.
Patient and public involvement
This research was conducted without patient involve-
ment. Patients were not invited to comment on the 
study design and were not consulted to develop patient- 
relevant outcomes or interpret the results. Patients were 
not invited to contribute to the writing or editing of this 
document for readability or accuracy.
results
A schematic overview of the entire data selection process 
can be found in figure 2. By using the above- mentioned 
search terms, a total of 380 publications were identified 
for screening, secondary inclusion included. The exact 
number of studies for each of the performed searches 
can be found in figure 1. After application of the inclu-
sion and exclusion criteria and removal of duplicates, the 
remaining 34 articles were deemed eligible for inclusion. 
To keep the overview updated, two additional papers 
(2- iminobiotin, lidocaine) that were not in the initial 
search strategy, but were suggested by the reviewers, were 
added in the revised version of the paper (both very 
recent publications, not in the initial search).
Characteristics of all retained (n=36) articles are 
provided in table 1. Most of the studies were prospective 
multicentre observational studies. The drugs reviewed 
ranged from those that are the current standard treatment 
for the occurrence of neonatal seizures (ie, phenobar-
bital), to various substances that have been hypothesised 
to have a neuroprotective effect in newborns suffering 
from HIE. Some PK parameters were much more 
frequently analysed than others. Total body clearance 
(C
L
) was calculated in all but one of the articles, whereas 
absorption was only relevant in three analyses as most of 
the drugs are administered by intravenous route. Only 
10 out of 36 articles included a normothermic control 
group in the study design. More common, the quantifica-
tion of the effect of TH on PK was based on data pooling 
or literature data, and subsequent use of population PK 
modelling approaches.
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Figure 2 Flow diagram of data selection and subsequent 
results.
Table 1 Study characteristics
Characteristic n
Type of study 36
  Prospective observational 28
  Retrospective observational 6
  Mixed 2
Drug
  Antiepileptics 9
   Phenobarbital* 6
   Midazolam* 3
   Lidocaine 1
  Antibiotics 12
   Gentamicin 8
   Amikacin 1
   Ampicillin 1
   Amoxicillin 1
   Benzylpenicillin 1
  Analgesic/sedative 3
   Morphine 3
  Various neuroprotective 11
   Erythropoietin 2
   Darbepoetin 2
   Topiramate 3
   Bumetanide 2
   Melatonin 1
   2- iminobiotin 1
Pharmacokinetic parameter
  Absorption 3
  Distribution volume 30
  Metabolic clearance 6
  Excretion 35
  Elimination half life† 18
Normothermic controls
  Yes 10
  No 26
*One study reported on both phenobarbital and midazolam 
pharmacokinetics.
†Elimination half life reflects both distribution and metabolic 
clearance/excretion.
In an attempt to facilitate comparison of the PK param-
eters for absorption, distribution, metabolism and excre-
tion described in the selected articles, the quantification 
of these parameters can be found in table 2a–f. Because 
of the different characteristics of each drug administered 
during the hypothermic period, the included studies as 
presented in table 2a–f were sorted by drug to facilitate 
comparison. In the subsequent synthesis, the effect of 
TH on each of the PK parameters will be discussed, illus-
trated by available findings for different drugs.
Absorption
The rate and amount of absorption of a drug determines 
the maximum plasma concentration (C
max
) and time 
needed to reach this peak concentration (t
max
). Absorp-
tion can best be assessed by bioavailability, which can 
be calculated based on the area under the curve after 
oral (AUC
PO
) versus intravenous (AUC
IV
) administra-
tion, using the following formula: AUC
PO
/AUC
IV
×100%. 
There are many factors that influence absorption after 
oral administration such as gastric emptying, food and 
physicochemical characteristics of the drug. These factors 
can be different in neonates when compared with adults, 
so that for example, differences in gastric emptying rate 
will affect the t
max
 for drugs that are mainly absorbed in 
the duodenum.13 However, absorption parameters are 
less relevant in the context of TH as all drugs except 
for topiramate and melatonin are administered intrave-
nously, where a bioavailability of 100% can be assumed.
Topiramate
Topiramate has been hypothesised to improve the 
neuroprotective effect of TH, with glutamate receptor 
inhibition as underlying claimed mechanism.14 In adults, 
it has a high oral bioavailability (±80%).15 As topiramate 
is usually not used in children younger than 2 years, there 
were no available PK data in neonates. In all three articles, 
the first dose of topiramate was 5 mg/kg and was admin-
istered via nasogastric tube.14 16 17 The two more recent 
studies went on to decrease the dose to 3 mg/kg for days 
2–5,16 17 whereas Filippi et al14 continued with 5 mg/kg 
for 3 days (table 2a). Both dosing regimens resulted in 
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Table 2a Topiramate and melatonin
Topiramate n Study type Absorption
V
D
 (L/
kg)
Metabolite C
L
 
(mL/kg/hour) C
L
 (mL/kg/hour) t
1/2
 (hour)
Filippi et al14 13 Prospective AUC=343.2 mg/L/hour / / MH=13.87
DH=15.72
MH=29
DH=49
Nuñez- Ramiro et al16 106 Prospective 
(RCT)
AUC=77.8 mg/L/hour / / 19.7 54.1
Marques et al17 52 Prospective
(RCT)
/ 0.976 / TH=12.6
Postwarm=15.3
↓20.8%=↓6.95%/
ºC
/
Melatonin             
Balduini et al21 
(Melatonine)
5 Prospective AUC
ss
=9.71 µg/mL/
hour t
abs
=2.8 hours
1.8 / 46.0 26.4
Table 2b Phenobarbital
Phenobarbital n Study type Absorption V
D
 (L/kg)
Metabolite C
L
 
(mL/kg/hour)
C
L
 (mL/kg/
hour) t
1/2
 (hour)
van den Broek et al35 31 Prospective / 0.986 / 4.914 140
Shellhaas et al37 39 Retrospective / 0.92 / 7.6 85
Filippi et al38 19 Prospective / 1.56 / 6.38 173.3
Favié et al34 113 Prospective / 1.03 / 2.394 298
Pokorná et al36 40 Prospective / 0.519 / 2.1 120
Šíma et al39 37 Prospective / 0.48 / 3.4 93.7
Table 2c Midazolam and lidocaine
Midazolam n Study type Absorption V
D
 (L/kg)
Metabolite C
L
 
(mL/kg/hour)
C
L
 (mL/kg/
hour) t
1/2
 (hour)
Welzing et al40 9 Prospective / 5.91 L 
(median 
weight not 
calculated)
/ 154.0 7.0
van den Broek et al41 53 Prospective / 1.93 OHM=0.7
HMG 0.02
268.0 5.0
Favié et al34 118 Prospective / 1.55 OHM=0.969
↓25.7%=↓8.6%/
ºC
HMG=0.055
100 /
Lidocaine             
Favié et al43 159 Mixed / 2.66 MEGX=431 506
↓21.8%=↓7.3%/
ºC
/
van den Broek et al42 48 Mixed / 3.11 MEGX=166 397.0
↓24.0%=↓8.0%/
ºC
5.5
Table 2d Morphine
Morphine n Study type Absorption V
D
 (L/kg)
Metabolite C
L
 (mL/
kg/hour) C
L
 (mL/kg/hour)
t
1/2
 
(hour)
Favié et al45 244 Prospective / 2.54 M3G=0.130
M6G=0.494
↓14.7%=↓4.91%/ºC
259.0
↓20.7%=↓6.89%/ºC
/
Róka et al44 16 Observational / / / ‘could not be 
calculated’
/
Frymoyer et al23 20 Prospective / 2.286
↓37.0%=↓12.3%/ºC
M3G=0.188
M6G=0.197
216.0
↓46.7%=↓15.6%/ºC
/
Continued
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Table 2e Antibiotics
Gentamicin n Study type Absorption V
D
 (L/kg)
Metabolite C
L
 
(mL/kg/hour) C
L
 (mL/kg/hour) t
1/2
 (hour)
Bijleveld et al49 47 Prospective / 0.897 / 60 (day 2)
77.4 (29%↑ day 5)
/
Liu et al46 55 Prospective / / / / /
Frymoyer et al50 29 Retrospective / 0.47 / 36.0 /
Ting et al47 46 Retrospective / NT=0.45
HT=0.41
/ NT=51.0
TH=33.0
↓35.3%=↓11.7%/ºC
NT=7.0
HT=9.6
Mark et al48 23 Retrospective / / / NT=50.0
HT=40.0
↓25%=↓8.3%/ºC
NT=6.6
HT=9.2
40%↑
Frymoyer et al51 52 Retrospective / / / 17.0 /
Cies et al77 12 Prospective / 0.87 / 132.0 /
Martínková et al78 35 Prospective / 0.40 / 46.0 /
Other antibiotics             
Cies et al24 
(Ampicilline)
13 Prospective / 0.52 / 25.8 /
Bijleveld et al53 
(Amoxicillin)
125 Prospective / 0.34 (V
C
) / PNA 0–4=90.0
PNA 5=14.0
55%↑
/
Bijleveld et al52 
(Benzylpenicillin)
41 Prospective / 0.62 (V
C
) / PNA 0–4=160.0
PNA 5=250.0
56%↑
/
Cristea et al54 
(Amikacin)
56 Retrospective / 0.832 / 49.5
↓40.6%=↓13.5%/ºC
/
Table 2f Erythropoietin, darbepoetin, bumetanide
Erythropoietin n Study type Absorption V
D
 (L/kg)
Metabolite C
L
 
(mL/kg/hour)
C
L
 (mL/kg/
hour) t
1/2
 (hour)
Frymoyer et al70 47 Prospective / V
C
=0.074
V
P
=0.096
/ 8.3 /
Wu et al68 24 Prospective / 0.095–0.178 / 7.7–15.6
C
L
↓ with dose↑
/
Roberts et al73 26 Prospective / 0.511 / 15.0 23.6
Baserga et al72 30 Prospective / / / 40.0–50.0 24–35
Miscellaneous             
Jullien et al81 
(Bumetanide)
14 Prospective / 0.23 / 19.8 8.4
Pressler et al82 
(Bumetanide)
14 Prospective / 0.23 / 19.8 8.4
Favié et al74
(2- iminobiotin)
12 Prospective / V
C
=0.138
V
P
=0.368
/ 113.8 2.9
AUC, area under the curve; C
L
, total body clearance; DH, deep hypothermia; HMG, 1- hydroxymidazolam glucuronide; MEGX, 
monoethylglycinexylidide; MH, moderate hypothermia; NT, normothermia; OHM, 1- hydroxymidazolam; PNA, postnatal age; RCT, randomised 
controlled trial; t
1/2
, half life; TH, therapeutic hypothermia; V
C
, central distribution volume; V
D
, volume of distribution; V
P
, peripheral distribution 
volume.
Table 2d Continued
a steady state within the therapeutic range of 5–20 mg/L 
but steady state was only reached after 48 hours.14 Filippi 
et al14 made a distinction between mild hypothermia 
(33°C–34°C) and deep hypothermia (30°C–33°C) to 
assess if the depth of hypothermia had an impact on PK. 
Although no significant differences were found between 
the observed plasma concentrations and the calculated 
parameters, a lower AUC
0–24
 and steady state plasma 
concentration (C
avg
), and a longer elimination half life 
(t
1/2
) were observed in the deep hypothermia group. 
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Table 3 Dosing recommendations of drugs used in newborns with hypoxic ischaemic encephalopathy undergoing 
hypothermia as provided at the Dutch paediatric formulary are compared with some recommendations reported in literature80
Recommendations as published Dutch paediatric formulary
LD MD LD MD
Phenobarbital 20–40 mg/kg / 20–40 mg/kg 2.5–5 mg/kg in 1–2 
doses/day
Morphine 50 µg/kg 5 µg/kg/hour 50–100 µg/kg over 
60 min
3–20 µg/kg/hour
Midazolam 0.05–0.1 mg/kg 0.05–0.1 mg/kg/hour 0.05 mg/kg 0.05–0.1 mg/kg/hour 
maximum 24 hours
Lidocaine >2.0–2.5 kg:2 mg/kg 
(10 min)
<2.5–4.5 kg:2 mg/kg 
(10 min)
6 mg/kg/hour (3.5 hours) → 
3 mg/kg/hour (12 hours) → 
1.5 mg/kg/hour (12 hours)
7 mg/kg/hour (3.5 hours) → 
3.5 mg/kg/hour (12 hours) → 
1.75 mg/kg/hour (12 hours)
2 mg/kg (10 min) 4 mg/kg/hour (6 hours) 
→ 2 mg/kg/hour 
(12 hours) → stop
Topiramate 15 mg/kg 5 mg/kg/day Not yet validated Not yet validated
Erythropoietin / 1.000 U/kg every 24 hours (3×) 
then every 48 hours (2×)
Not yet validated Not yet validated
Darbepoetin / 10 mcg/kg every 7 days (2×) Not yet validated Not yet validated
Gentamicin / 4–5 mg/kg every 36 hours (5×) / 5 mg/kg every 36 hours
Amikacin / 15 mg/kg every 36 hours Not yet validated Not yet validated
LD, loading dose; MD, maintenance dose.
Due to the small sample size the differences were not 
statistically significant, however, it is possible that these 
effects would become statistically significant in a larger 
study population.16 Nuñez- Ramiro et al16 and17 Marques 
et al17 both used the same dosing strategy, but only the 
first research group calculated the AUC
0–24
, which was 
considerably lower than the one calculated by Filippi et 
al14 (see table 2a). Both groups concluded that a 5 mg/
kg loading dose (LD) and a 3 mg/kg as a maintenance 
dose (MD) were too low and the time needed to reach 
therapeutic concentrations too long.14 16 Since there is 
a strong correlation between serum level and seizure 
control or neuroprotective effects, it is desirable to reach 
steady state more quickly. The PK modelling suggests that 
an LD of 15 mg/kg followed by an MD of 5 mg/kg would 
lead to 90% of patients reaching therapeutic concentra-
tions after 24 hours.14 16 17 Though the AUC was calcu-
lated in two of three studies, this parameter does depend 
on absorption, and is affected by subsequent distribu-
tion, metabolism and elimination. Unfortunately, in the 
absence of intravenous PK data in neonates, quantifica-
tion of bioavailability and the impact of asphyxia and TH 
cannot be assessed.
Melatonin
The hormone melatonin, which regulates circadian 
rhythm, is produced by the pineal gland. In several 
animal models of HIE it has been shown to augment 
the neuroprotective efficacy of hypothermia by inhib-
iting apoptosis, stimulating antioxidant enzymes and by 
modulating the inflammatory response.18–20 Balduini 
et al 21 are the first to have conducted a study with 
melatonin in human neonates with only five infants 
included, in order to study the PK (table 2a). The 
authors administered melatonin by continuous drip 
over nasogastric/orogastric tube at 0.5 mg/kg over 
4 hours, after which the absorption time was estimated 
to be 2.8 hours.21 Larger clinical studies to evaluate the 
efficacy of melatonin in neonates with HIE are there-
fore needed.
distribution
Distribution is typically expressed as volume of distribu-
tion (V
D
) which represents a virtual space that the drug 
has been dissolved in. V
D
 depends on substance char-
acteristics and patient factors which can be different 
between neonates and adults. For example, neonates 
have a proportional higher body water content which 
can imply that the V
D
 per kg is higher for water- soluble 
compounds.22
Out of the 36 articles included in this analysis, 
30 reported on aspects of the V
D
, sometimes based 
on a central (V
C
) and peripheral (V
P
) distribution 
volume. However, only 2/30 articles described a signif-
icant impact of the TH on distribution. Interestingly, 
Frymoyer et al describe a 37% decrease in the V
D
 of 
morphine (8.0 L in TH vs 12.7 L for normothermia for 
an infant with mean birth weight of 3.5 kg), whereas Cies 
et al, on the other hand, found a 30% increase of V
D
 for 
ampicillin.23 24 Both studies compared their own data to 
earlier reported studies in literature, instead of a data set 
of normothermic controls integrated in the same anal-
ysis.25 26
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Clearance: metabolisation and excretion
After absorption and distribution, drugs are slowly 
cleared from the body by one of three ways: (1) excre-
tion, unchanged by the kidneys, (2) elimination via other 
excretion routes such as bile, sweat, saliva or milk glands, 
and/or (3) metabolisation mainly by the liver into metab-
olite(s) that can be both an inactive substance or a more 
active molecule compared with the mother compound. 
Such metabolites commonly subsequently undergo addi-
tional metabolism or are eliminated by renal or other 
excretion routes. Quantitatively, the largest group of 
metabolising enzymes is the cytochrome P450 (CYP450) 
mono- oxygenase family. Tortorici et al27 established that 
hypothermia impacted hepatic drug elimination by 
decreasing the activity of the CYP450 system, based on 
studies in brain- injured adults and healthy volunteers. 
However, such findings need to be integrated with 
isoenzyme- specific ontogeny in neonates.12 The sum of 
excretion in the urine of both the intact substance and 
metabolites that have been produced by the liver, further 
metabolisation and excretion into bile, sweat, saliva or 
milk make up the C
L
.12
If, for example, a substance is primarily cleared by excre-
tion in the urine, renal function is the principal deter-
minate of clearance. The Cochrane systematic review on 
TH could not observe any significant differences in urine 
output in neonates who underwent TH compared with 
those who did not. Furthermore, meta- analysis showed 
that TH did not cause a significant difference in the 
occurrence of acute kidney injury.2 This suggests that 
asphyxia, and not the intervention, is the major determi-
nant of altered renal elimination clearance. In the first 
week after birth there is maturation in renal function, 
the rate of which depends on the gestational age (GA) at 
birth, with premature neonates displaying a slower matu-
ration than term neonates.28 Creatinine is a degradation 
product of creatine which is produced by the muscles at a 
near constant speed and subsequently filtered passively by 
the kidneys into the urine. Consequently, under normal 
circumstances, it is a good biomarker for renal clear-
ance, however studies show that birth creatinine reflects 
maternal creatinine values to subsequently peak in the 
first 48 hours of life irrespective of the presence of acute 
kidney injury related to asphyxia.12 29 30 Therefore, serum 
creatinine might not be a good indicator of renal clear-
ance for neonates in the first days after birth.31 32 In total, 
13 out of 36 studies demonstrated a significant decrease 
in total clearance as high as 46% during TH (table 2a–f).
Phenobarbital
Neonatal seizures in the context of HIE are treated in 
first line with phenobarbital, an antiepileptic drug that 
in adults has been replaced by other antiepileptic agents 
with fewer adverse effects. Phenobarbital is metabo-
lised in the liver mostly by CYP2C9 to inactive metabo-
lites, which are then renally excreted together with 25% 
of unchanged phenobarbital.33 None of the included 
studies measured the serum levels of phenobarbital 
metabolites so no final conclusions can be drawn about 
metabolism.34–39 About 66% of neonates with HIE and 
seizures respond to phenobarbital.34 35 Pokorná et al36 
observed decreased clearance during TH, although 
these changes were not statistically significant (table 2b). 
Similarly, none of the other included studies were able 
to detect a substantial effect of TH on the PK parameters 
measured.34 35 37–39 The therapeutic window for pheno-
barbital is 20–40 mg/L, which can be attained with an LD 
of 20 mg/kg that can be increased up to a maximum of 
40 mg/kg if seizure control is not attained.35 38 However 
a more recent study suggests to start at a higher dose of 
30 mg/kg.34 Some of the authors also continued with an 
MD ranging from 1.5 to 8 mg/kg after the LD depending 
on the study.36 38 Other factors that were investigated for 
an effect on PK parameters were the severity of HIE and 
the influence of other drug.36 The severity was found 
to have an effect on phenobarbital clearance, likely 
because of a decreased cardiac output which leads to 
less blood flow to the kidneys and liver and a reduction 
in metabolic capacity. This suggests that disease severity 
is a more prominent covariate of phenobarbital clear-
ance compared with TH.36 Furthermore, concomitant 
dobutamine administration also had an effect on pheno-
barbital clearance (although the authors suspect this was 
an artefact of the small sample size39).
Midazolam
A model compound of a drug metabolised by 
a CYP450 enzyme is midazolam, converted by 
CYP3A to 1- hydroxymidazolam and successively to 
1- hydroxymidazolam glucuronide (HMG), both of which 
are sedative and further excreted by renal route. Mida-
zolam is used as an add- on antiepileptic drug when seizure 
control with phenobarbital monotherapy is inadequate 
and provides an additional 23% of patients with seizure 
control. Intriguingly, none of the studies on midazolam 
showed an effect of TH on midazolam clearance.34 40 41 
However, Favié et al reported on a significant reduction 
of the clearance of HMG (8.6%/°C), likely reflecting the 
impact of renal impairment34 40 41 (table 2c). Midazolam 
is usually concomitantly used with phenobarbital, which 
is an inducer of CYP3A. This effect has been quantified, 
so that midazolam metabolic clearance is increased by 
2.33- fold during comedication with phenobarbital.34 
Thus, if another antiepileptic drug is used as a first- line 
agent instead of phenobarbital, the dose of midazolam 
should be reduced by about 50%.34 A point of attention 
is the occurrence of hypotension during treatment with 
midazolam as blood pressure and plasma concentrations 
of midazolam have a direct relationship, with blood pres-
sure dropping by 3.6 mm Hg for every increase in plasma 
concentration of 0.1 mg/L.41
Lidocaine
If there is still no seizure control after adding midazolam, 
lidocaine can be added as a third- line treatment, which 
is effective in 91% of the patients where seizure control 
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could not be achieved with phenobarbital and mida-
zolam alone.42 43 Lidocaine is a drug frequently used as a 
local anaesthetic or antiarrhythmic agent and is predomi-
nantly metabolised by CYP3A into the active monoethylg-
lycinexylidide and subsequently glycinexylidide, which 
is an inactive metabolite. The clearance of lidocaine was 
shown to be decreased by 24% (or 8.0%/°C) during 
TH.42 The extent of the impact of TH on lidocaine PK 
has recently been confirmed (decrease 21%, 7.26%/°C) 
in a further extended cohort of patients, including 49 
neonates undergoing TH (prospective validation).43
Morphine
Morphine is metabolised in the liver into two metab-
olites by the enzyme UDP- glucuronosyltransferase 
2B7 (UGT2B7): morphine-3- glucuronide (M3G) and 
morphine-6- glucuronide (M6G). Both morphine and its 
less abundant metabolite M6G are analgesic and seda-
tive, whereas M3G is inactive. Róka et al44 concluded 
that the clearance of morphine and its metabolites were 
decreased during TH (table 2d). This conclusion was 
based on differences in median morphine plasma concen-
tration (292 ng/mL (137–767 ng/mL) during TH to 
206 ng/mL (88–327 ng/mL) in normothermic neonates 
(p=0.014)) even though the normothermic newborns on 
average had received a higher dose of morphine. Unfor-
tunately, the authors were unable to report on morphine 
PK. It is therefore not possible to compare the results 
with the subsequent studies. However, it did raise the 
question of altered clearance under TH and inspired 
others. Frymoyer et al23 compared the PK parameters 
observed in their prospective study during TH to the 
data provided by Knibbe et al25 during normothermia. 
They concluded that morphine clearance was decreased 
by 46.7% (15.6%/°C) in newborns treated with TH.23 An 
interesting finding in this study was that M6G accumula-
tion is dependent on the serum creatinine. Monte Carlo 
simulations suggested that an LD of 50 µg/kg followed 
by an MD of 5 µg/kg or intermittent dosing of 40–50 µg/
kg every 6 hours is recommended to stay within the ther-
apeutic window.23 The results of these simulations were 
seconded by the findings of two open- label prospective 
studies conducted in the Netherlands reported by Favié 
et al.45 They found a decreased morphine clearance of 
20.7% (or 6.98%/°C) and of metabolites M3G and M6G 
of 14.7% (or 4.91%/°C) during TH. The authors subse-
quently observed that over the subsequent first 5 days of 
life there is an increase in clearance, the phenotypic final 
result of maturation of UGT2B7 activity, disease recovery 
and finalisation of TH.23 44 45
Antibiotics
Gentamicin is an aminoglycoside antibiotic administered 
empirically to most neonates with HIE and is predom-
inantly eliminated renally. Ideally the dose should 
generate a peak concentration of 10–12 mg/L and a 
trough concentration not exceeding 2 mg/L as this could 
cause ototoxicity and nephrotoxicity. Liu et al46 were the 
first to study the effect of TH on gentamicin PK (table 2e). 
They compared trough concentrations between normo-
thermic and hypothermic group, which were not signifi-
cantly different, but were, with a dose of 4–5 mg/kg every 
24 hours, above 2 mg/L in 36%–44% of neonates. They 
did however not calculate or measure other PK parame-
ters but set the scene for better PK studies.46 Two retro-
spective studies observed a decrease by 25.0%–35.3% (or 
8.3%–11.7%/°C) in the C
L
 in neonates undergoing TH, 
and a significant increase in t
1/2
.47 48 Another study found 
an increase of 29% in clearance on postnatal age day 5, 
which can be considered as steady- state normothermia 
after rewarming.49
With regard to gentamicin dosing, many different 
schemes have been explored with an increasing 
interval between doses, ranging from 2.5 mg/kg every 
12 hours47 to 4 mg/kg every 24 hours48 to 4–5 mg/kg 
every 36 hours.48–51 Just increasing the dosing interval 
from 24 to 36 hours reduced the number of newborns 
with trough concentrations under 2 mg/L from 62% to 
96% without compromising on the percentage reaching 
the peak concentration.51 But whatever dosing regimen 
is used, all studies recommend therapeutic drug moni-
toring (TDM), and the same holds true for other amino-
glycosides (like amikacin).49
Apart from gentamicin, other antibiotics have also 
been investigated: ampicillin, amoxicillin, amikacin and 
benzylpenicillin.24 52–54 The PharmaCool study group 
observed a 55%–56% increase in clearance of amoxicillin 
and benzylpenicillin after postnatal age day 5, which 
can be considered as reaching normothermic steady 
state.52 53 Based on subsequent simulations, the authors 
suggest implementing a GA- dependent dosing regimen, 
with a lower dose for GA of 36–37 weeks. Both Cies et 
al24 and Cristea et al54 also quantified the decrease in 
clearance (by 69.3% and 40.6% respectively) during TH, 
leading for the latter in an extension in dosing interval to 
42 hours instead of 30 hours. The percentage of neonates 
reaching toxic trough concentrations is thereby reduced 
from 40%–76% to 14%–17%.54
Erythropoietin, darbepoetin and 2-iminobiotin
As second- line interventions in addition to TH, certain 
drugs have also been investigated for their neuroprotec-
tive effect.55–57 Erythropoietin (EPO), most well known 
for its haematopoietic effect, is produced by the kidneys 
and the brain cells (astrocytes, neurons, oligodendro-
cytes). EPO binds to the EPO receptor which is expressed 
by these same cells as well as by microglial and endothe-
lial cells. It is proposed to have an anti- inflammatory 
effect in addition to inhibition of cell death and promo-
tion of angiogenesis and development of new neurons 
and oligodendrocytes.58–61 Combining EPO with TH is 
therefore hypothesised to have an additive neuroprotec-
tive effect.57 62–65 The synthetic darbepoetin mimics the 
effects of EPO, but has a longer t
1/2
, enabling the use 
of a longer dosing interval (table 2f). Only a very small 
amount (<5%) of EPO, and thus darbepoetin, is excreted 
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unchanged by the kidneys.66 The majority is degraded in 
the body, possibly by intracellular degradation, of which 
the exact mechanisms are for the main part unknown.67
Wu et al68 performed a phase I prospective study to 
determine the optimal dosing of EPO in humans by 
testing different doses ranging from 250 U to 2500 U/
kg per dose every 48 hours. This article shows that with 
an increase in dose, clearance decreased from 15.6±6.3 to 
7.7±0.9 mL/kg/hour. The dose of 1000 IU/kg had the 
best AUC and C
max
 for the administered dose (similar 
to those of a study with rats).69 Frymoyer et al,70 who 
included both the phase I trial mentioned above and the 
subsequent phase II study, found a C
L
 of 8.3 mL/kg/hour 
which is considerably lower than a study reported for 
premature extremely low birthweight neonates (13.1 mL/
kg/hour).71 They also concluded that neonates with HIE 
receiving TH will typically have a 50% higher exposure 
after the same EPO dose. The recommended dose used 
was 1000 IU/kg every 24 hours for three doses and then 
two doses every 48 hours. The phase II trial found a clin-
ical benefit of administering the EPO with significantly 
better brain MRI and motor function at 12 months.62 The 
corresponding phase III is momentarily still in progress.
Baserga et al72 administered two doses of the EPO- 
derived molecule Darbe (darbepoetin), one on day 0 
and one on day 7. They divided the neonates into two 
treatment groups with one group receiving 2 µg/kg while 
the other was administered a higher dose of 10 µg/kg. 
A third placebo control group was needed to determine 
the baseline EPO as the quantification machines cannot 
distinguish between endogenously produced EPO and 
the synthetic Darbe. The group receiving the higher dose 
had an AUC that best matched that of animal studies.69 
Roberts et al73 also concluded that GA is inversely 
correlated with C
L
, meaning that preterm neonates have 
a higher clearance than term neonates.
2- Iminobiotin is another potential neuroprotective 
agent.74 A dose seeking (to target exposure) study in two 
consecutive cohorts of six neonates undergoing TH has 
recently been reported, and dosing for the second cohort 
had to be adapted to further compensate for the renal 
impairment associated with asphyxia. The median clear-
ance in these 12 cases was 0.38 L/hour, but cannot be 
compared with data in non- cooled or healthy neonates.74
dIsCussIon
Compared with the latest structured review (2015) that 
provided information on the PK during TH for four 
compounds (gentamicin, topiramate, phenobarbital, 
morphine), the current systematic search provided PK 
data on 15 compounds, reflecting the impressive and 
relevant progress made in this specific field of neonatal 
pharmacology since 2015.75
Based on the available data, it is difficult to compare 
PK data in HIE newborns with or without TH due to the 
small number of studies that include normothermic HIE 
controls, as TH is now standard practice in most countries. 
It would thus be unethical not to offer the best care (ie, 
TH). Therefore, the control group are often neonates 
who do not suffer from HIE, which in turn makes it diffi-
cult to disentangle the effect of HIE from TH.12
Phenobarbital is a relatively old antiepileptic drug, 
which in adults has been substituted by newer agents. 
However, it remains one of the most effective antie-
pileptic drugs for neonatal seizures.34–39 Pending the 
outcome of ongoing comparative studies on the use 
of phenobarbital or levetiracetam as first- line antiepi-
leptic,76 it is possible that levetiracetam or another antie-
pileptic drug will replace phenobarbital. However, as 
phenobarbital has an inducing effect on the metabolism 
of midazolam (which is often coadministered), if pheno-
barbital were to be replaced by levetiracetam, the dosage 
of midazolam needs to be reduced if we aim for similar 
exposure.34 Along the same line, and because levetirac-
etam is mainly eliminated by renal route, it is reasonable 
to except a similar decrease in renal clearance as quan-
tified for aminoglycosides (table 2e).46–51 54 77 78 Such an 
‘informed’ approach to anticipate for the impact of renal 
impairment on dosing to attain a given target exposure 
has been described in the 2- iminobiotin paper.74
This article only explored the impact of HIE+TH on 
the PK in neonates. But in the clinical setting, pharma-
codynamics, the effect that the drug has on the body, 
also needs to be considered. For antiepileptic drugs, 
this means the seizure control response documented by 
amplitude- integrated electroencephalography (aEEG).35 
The only study in which this was quantified until present 
is van den Broek et al35 who found that administering 
phenobarbital to neonates undergoing TH reduced 
transition from continuous normal voltage to discontin-
uous normal voltage aEEG background level. The only 
other pharmacodynamic parameter evaluated is target 
attainment of antibiotics which was calculated using the 
ƒT>MIC ratio (minimal inhibitory concentration), which 
is the time that the free concentration of the substance 
is higher than the minimal inhibitory concentration.24 53 
Although Cies et al24 administered 100 mg/kg ampicillin 
every 8 hours, their modelling predicted that 25 or 
50 mg/kg every 24 hours would actually be sufficient to 
attain a target of 50% and even 100% of time above MIC. 
Bijleveld et al53 also used simulations to recommend a 
GA- dependent dosing regimen: 50 mg/kg/day of amox-
icillin for GA of 36–37 weeks and 75 mg/kg/day for GA 
38–42 in three doses for 7 days, which result in target 
attainment of 100% for Streptococcus agalactiae and Listeria 
monocytogenes. The Dutch paediatric formulary currently 
advises a dose of 75 mg/kg/day in three doses for all 
neonates who are younger than 7 days postnatal age and 
have birth weight of over 2 kg.79
The Dutch paediatric formulary is an illustration on 
how published data can subsequently be assessed and 
provided as specific dosing regimens to facilitate knowl-
edge diffusion and access. Because of this assessment 
(one of the criteria is prospective validation, a confirma-
tion of a suggested dosing regimen), not all published 
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data are immediately present in this formulary (table 3).80 
Furthermore, TDM can be used to verify if a given drug 
exposure is within the therapeutic range. This mainly 
relates to drugs where TDM is routinely performed like 
phenobarbital or aminoglycosides (gentamicin, amik-
acin), but may be considered also for midazolam and its 
metabolite (prolonged sedation related to metabolite 
accumulation), lidocaine (cardiac effects) or topiramate 
(therapeutic failure if used as antiepileptic, also relevant 
for phenobarbital, midazolam, lidocaine).12 75
ConClusIon
The aim of this paper was to determine the effect of 
lowering the core body temperature of the neonate with 
HIE, on the PK of different drugs used during TH. This 
was evaluated by comparing values for the different PK 
processes: absorption, distribution, metabolisation and 
elimination. Depending on drug and elimination route, 
TH has clinical relevant effects on PK.
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